Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

220.75
+9.644.56%
Post-market: 220.750.00000.00%19:52 EDT
Volume:1.23M
Turnover:273.29M
Market Cap:11.56B
PE:-58.58
High:229.62
Open:212.71
Low:212.44
Close:211.12
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:2.63
T/O Rate:2.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:138.81
PE(LYR):-59.95

Loading ...

Axsome Therapeutics - FDA Sets Pdufa Target Action Date of May 1, 2027 for Axs-12 Nda

THOMSON REUTERS
·
Jul 15

Axsome Therapeutics - FDA Does not Plan Advisory Committee Meeting for Axs-12 Nda

THOMSON REUTERS
·
Jul 15

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for Axs-12 for the Treatment of Cataplexy in Narcolepsy

THOMSON REUTERS
·
Jul 15

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Axsome Therapeutics (AXSM) and Nurix Therapeutics (NRIX)

TIPRANKS
·
Jul 14

Axsome Therapeutics to Report Q2 Financial Results, Host Conference Call

Reuters
·
Jul 14

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

GlobeNewswire
·
Jul 14

Axsome Therapeutics Down over 7%, on Pace for Largest Percent Decrease Since April 2025

Dow Jones
·
Jul 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 10

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

TIPRANKS
·
Jul 08

Axsome Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Pediatric ADHD

Reuters
·
Jul 07

Axsome Therapeutics Initiates Focus-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (adhd)

THOMSON REUTERS
·
Jul 07

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

GlobeNewswire
·
Jul 07

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves

Simply Wall St.
·
Jul 06

Axsome Therapeutics CEO Herriot Tabuteau Disposes of 49,666 Common Shares Worth $11.93 Million

Reuters
·
Jul 02

Axsome Therapeutics doses first patient in FOCUS-3 trial

TIPRANKS
·
Jun 26

Axsome Doses First Patient in Focus-3 Phase 3 Trial of Solriamfetol for Adolescent ADHD

Reuters
·
Jun 26

Axsome Therapeutics Initiates Focus-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (adhd)

THOMSON REUTERS
·
Jun 26